Combining Chemical Genetics and Cancer Immunotherapy
This article was originally published in Start Up
Two years ago, a team at Stanford described a new "chemical genetics" technique--a more precise way to use small molecules to perturb gene products and living systems. Now they have published more data on the system. And of acute interest to drug developers, they have linked the work to therapeutic applications in cancer immunotherapy, showing the ability to regulate secreted proteins such as IL-2 and TNF.
You may also be interested in...
Teasing Out Mechanisms of Small-Molecule Kinase Inhibition
Even as kinases remain a popular target in oncology for industry, two recent papers show how much we have yet to learn about how to interfere with these molecules. These most recent laboratory studies help explain the confusing observation that the very act of inhibiting a kinase with a drug can also "prime" phosphorylation of that target, which in some cases can actually enhance tumor activity.
Amping Up Dendritic Cells
Researchers are looking for ways to better stimulate dendritic cells (DCs, the antigen presenting cells that initiate and control many aspects of the immune response) in the hopes of creating potent vaccines against tumors and infectious diseases. A recent paper highlights progress on the DC targeting front using a DNA vaccine strategy, but is also a reminder that the immunotherapy field has a long way to go.
A New Perspective on Cancer Immunotherapy
Many believe that for therapeutic cancer vaccines, a more flexible two-stage system of proof-of-principle trials followed by efficacy trials should replace the current Phase I-III structure. That's because the paradigm used for oncology drug development is based on criteria developed for cytotoxic agents, which present a very different toxicity profile, metabolism, and manner of biological and clinical response.